Mukka Proteins allots 2 crore warrants worth Rs 47 crore

Mukka Proteins Limited allotted 2 crore preferential convertible warrants during the quarter ended September 30, 2026, with an aggregate potential equity issue value of Rs 47 crore at Rs 23.50 per warrant. Mukka Proteins received Rs 11.75 crore upfront, while the remaining Rs 35.25 crore is payable only if holders exercise their rights within 18 months of allotment.

What did Mukka Proteins allot and at what price?

Mukka Proteins allotted 2 crore convertible warrants on a preferential basis at an issue price of Rs 23.50 each, creating a potential aggregate issue value of Rs 47 crore. Each warrant gives its holder the right to subscribe to one fully paid equity share with a face value of Rs 1, and the issue price includes a premium of Rs 22.50 per warrant.

The warrant allotment occurred during the quarter ended September 30, 2026, although the filing does not state the precise allotment date or identify the allottees. The Board of Directors took the unaudited consolidated results, including the warrant disclosure, on record on November 7, 2026. Mukka Proteins reports one operating segment, Fish & Insects Protein, and has not specified a project, geography or segment for use of the potential proceeds.

The instrument is a warrant rather than an immediate allotment of 2 crore equity shares. The filing says each warrant carries a right exercisable by the holder to subscribe to one share, so the Rs 47 crore represents the full value if all warrants are exercised, rather than cash received at allotment.

How much warrant money has Mukka Proteins received?

Mukka Proteins has received Rs 11.75 crore from the warrant holders, equal to 25% of the Rs 47 crore aggregate issue value. The balance of Rs 35.25 crore, representing 75% of the issue price, is payable at the time a holder exercises the conversion option.

The consolidated cash-flow statement for the half year ended September 30, 2026 reports Rs 11.75 crore as net proceeds from issue, net of share-issue expenses. The filing does not say that the remaining Rs 35.25 crore has been called or received, and it makes the payment conditional on the holders exercising their warrants within the stated period.

Mukka Proteins reported cash and cash equivalents of Rs 23.532 crore at September 30, 2026, compared with Rs 12.881 crore at March 31, 2026. The half-year cash flow also included Rs 8.3605 crore of changes in non-current borrowings, Rs 1.1192 crore of reduction in current borrowings and Rs 12.930 crore of investing cash outflow, separate from the warrant proceeds.

When can Mukka Proteins warrant holders exercise their rights?

Mukka Proteins has given warrant holders 18 months from the allotment date to exercise their right to subscribe to equity shares. On exercise, the holder must pay the remaining 75% of the Rs 23.50 issue price and can subscribe to one fully paid Rs 1 face-value share for each warrant.

The filing does not disclose an exercise timetable within the 18-month window, whether holders will exercise together, or the accounting treatment if warrants are not exercised. It only specifies the two payment stages: 25% received at allotment, amounting to Rs 11.75 crore, and 75% payable when the conversion option is exercised.

Mukka Proteins reported paid-up equity share capital of Rs 30 crore at September 30, 2026, with a face value of Rs 1 per share. If all 2 crore warrants are exercised, the share count implied by that capital would rise from 30 crore to 32 crore shares, a calculated increase of 6.25% in the post-exercise share count.

How do the warrants compare with Mukka Proteins financial results?

Mukka Proteins reported consolidated revenue from operations of Rs 495.282 crore for the quarter ended September 30, 2026, compared with Rs 236.081 crore for the quarter ended September 30, 2025. Consolidated profit after tax rose to Rs 17.727 crore from Rs 6.884 crore in the same comparison, while the company received Rs 11.75 crore in warrant proceeds during the half year.

For the half year ended September 30, 2026, revenue from operations reached Rs 970.086 crore, compared with Rs 400.962 crore in the corresponding 2025 period. Profit after tax was Rs 36.361 crore, versus Rs 8.473 crore a year earlier. These are operating-period results, whereas the warrant transaction is a financing arrangement with a conditional second payment.

Mukka Proteins generated Rs 827.580 crore of half-year revenue outside India and Rs 142.506 crore within India in the 2026 period. In the corresponding 2025 half year, outside-India revenue was Rs 294.232 crore and India revenue was Rs 106.730 crore. The filing nevertheless treats Fish & Insects Protein as one operating segment and does not connect warrant proceeds to either geography.

What could the warrants change in Mukka Proteins capital structure?

Mukka Proteins has received Rs 11.75 crore immediately and could receive a further Rs 35.25 crore if all warrants are exercised within 18 months. Full exercise would result in 2 crore new equity shares and total warrant consideration of Rs 47 crore, while non-exercise treatment is not disclosed in the filing.

Mukka Proteins reported total equity of Rs 528.181 crore at September 30, 2026, compared with Rs 528.775 crore at March 31, 2026. Total assets increased to Rs 1,860.251 crore from Rs 1,621.127 crore, and total current liabilities rose to Rs 1,198.549 crore from Rs 1,048.929 crore over the same period. These balance-sheet figures provide context for the upfront receipt but do not establish its intended deployment.

Current borrowings were Rs 724.477 crore at September 30, 2026, down from Rs 735.669 crore at March 31, 2026, while non-current borrowings increased to Rs 115.707 crore from Rs 32.101 crore. Mukka Proteins has not described the warrant issue as funding debt repayment, working capital, capital expenditure or a particular business initiative, so a specific use of the Rs 47 crore potential proceeds cannot be inferred.

Conclusion

Mukka Proteins has created a potential Rs 47 crore equity issuance through 2 crore preferential warrants priced at Rs 23.50 each. The company has received Rs 11.75 crore at allotment, but the remaining Rs 35.25 crore and the issue of underlying shares depend on warrant holders exercising their rights.

The key disclosed event to watch is the 18-month exercise window from the allotment date. Future filings may show whether holders pay the balance, how many shares Mukka Proteins issues, and whether the company later discloses an intended use for the proceeds.